FDA Approved Drugs » 2012
Medical Areas: Ophthalmology | Family Medicine | Infections and Infectious Diseases
View By:Year | Company | Conditions | Therapeutic Areas | Drug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Sigma Tau Pharmaceuticals
Approval Status: Approved October 2012
Treatment Area: corneal cystine crystal accumulation due to cystinosis
Cystaran (cysteamine hydrochloride) is a cystine-depleting agent which lowers the cystine content of cells in patients with cystinosis, a rare genetic disorder. Cystine is a naturally occuring amino acid. Cystinosis causes an accumulation cystine within cells; the cystine eventually forms crystals that build up and damage the cells.
Cystaran is specifically approved for the treatment of corneal cystine crystal accumulation in adults and children with cystinosis.
Cystaran is supplied as an ophthalmic solution for topical administration. The recommended dose one drop in each eye, every waking hour. The solution should be discarded after one week of use.
FDA ApprovalThe FDA approval of Cystaran was based on on three controlled clinical trials conducted by the NIH, in approximately 300 subjects. The primary efficacy endpoint was the response rate of eyes that had a reduction of at least 1 unit in the photo-rated Corneal Cystine Crystal Score (CCCS) at some time point during the study when baseline CCCS >1, or a lack of an increase of more than 1 unit in CCCS throughout the study when baseline CCCS <1. Study 1 combined the data from three smaller studies. For eyes with a lower baseline of CCCS <1, the response rate was 13%. For eyes with a higher baseline of CCCS >1, the response rate was 32%. Study 2 evaluated ocular cystinosis patients who had a baseline of CCCS >1. The response rate was 67%. Study 3 also evaluated ocular cystinosis patients who had a baseline of CCCS >1, the response rate was 33%.
Adverse effects associated with the use of Cystaran may include, but are not limited to, the following:
Cystaran (cysteamine hydrochloride) acts as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides and reduces corneal cystine crystal accumulation.
For additional information regarding Cystaran or corneal cystine crystal accumulation and cystinosis, please visit the Sigma Tau Products web page.
Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.
The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.
© Copyright 2000-2009 Multiple Sclerosis Foundation - All Rights Reserved